About
LicensingBioLink WeeklyJob BoardNewsContact Us
Princeton, NJ — US-China Biopharma

Catalyzing US‑China
Biotech & Pharma
Partnerships

BioRich International connects leading pharmaceutical companies and biotech innovators across the US-China corridor — facilitating licensing deals, capital connections, and R&D collaboration.

Explore Our ServicesRead BioLink Weekly
0+
Chinese Clients
0+
Projects
0+
MNC Connections
0+
Years of Experience
Our Services

Comprehensive Support Across
the Deal Lifecycle

Licensing Deals

Out-licensing & in-licensing facilitation between Chinese biotechs and global pharma. 250+ clients, 400+ projects.

Learn more

Capital & Talent

We connect biopharma companies with pre-screened US venture capital and provide executive and scientific recruitment support — drawing on one of the most extensive personal networks in US-China biopharma to place the right people at the right time.

Learn more

CRO/CDMO Matching

Selecting the right contract research or manufacturing partner is one of the highest-stakes decisions in drug development. We leverage deep relationships across the China CRO/CDMO landscape — and beyond — to match clients with partners whose capabilities align with their program requirements.

Learn more

Market Research

Understanding the China biopharma market requires specialized knowledge that is difficult to source externally. Our proprietary market reports, combined with BioLink Weekly, provide the depth and currency needed to make confident strategic decisions.

Learn more
About BioRich

A Trusted Partner at the
Intersection of East and West

Founded by John Xu, MD, MBA, MS — with over 30 years of experience at Bristol Myers Squibb, Wyeth, WuXi AppTec, and CrownBio — BioRich International operates at the nexus of US and Chinese biopharma. We bridge the information, relationship, and cultural gaps that prevent high-potential deals from closing.

Our network encompasses 250+ Chinese biotech clients, direct relationships with BD&L leadership at 25+ multinational corporations, and active engagement with more than 10 US venture capital firms.

Meet our leadership
"

The biggest obstacle to deal-making is not interest or capital — it is information asymmetry. BioLink Weekly exists to close that gap.

John Xu, MD, MBA, MS

Founder & President, BioRich International

BioLink Weekly

Intelligence for US-China Biopharma Dealmakers

View all issues →
Issue 11June 23, 2026

Antengene Hands MPM-Backed K2 a CDH6xCD3 TCE in a ~$1B China-Out Deal; Lilly and Biogen Add Bolt-Ons as the FDA Clears the First Oral Carbapenem

The June 16-23 window restarted the China-out licensing engine after two M&A-led weeks. Antengene granted MPM BioImpact-established K2 Therapeutics exclusive ex-Greater China rights to ATG-106, a preclinical CDH6xCD3 bispecific T-cell engager, for about $20M upfront and near-term plus up to $960.5M in milestones (announced June 22), with an option on a second undisclosed TCE on similar terms. Two US bolt-on acquisitions rounded out dealmaking - Eli Lilly's purchase of non-opioid pain developer 4E Therapeutics (undisclosed, June 16) and Biogen's up-to-$1B acquisition of immunology biotech RayThera (June 17). On the science side, the FDA approved Spero/GSK's Utebzi (tebipenem pivoxil), the first oral carbapenem (June 17); MoonLake reported strong Week 52 VELA data for sonelokimab in hidradenitis suppurativa (June 21); and Definium's single-dose lysergide ODT (DT120) met its Phase 3 primary endpoint in major depression (June 22).

Read issue
Issue 10June 16, 2026

GSK's $10.6B Nuvalent Buy Headlines an M&A-Led Week; EHA 2026 Delivers Practice-Shifting Phase 3 Data in Myeloma, Lymphoma and Sickle Cell

The June 9-16 window was M&A-led and US/EU-centric. GSK agreed to acquire Nuvalent for about $10.6B (announced June 9), adding next-generation, highly selective ROS1 and ALK inhibitors for non-small-cell lung cancer, while PharmaEssentia announced a $36.5M bolt-on of its Canadian commercialization partner FORUS Therapeutics (June 11). No major China-out licensing deal was announced in-window. EHA 2026 (Stockholm, June 11-14) carried the clinical news, with Phase 3 readouts from Johnson & Johnson (MonumenTAL-3 in myeloma), Incyte (frontMIND in DLBCL) and Agios (RISE UP in sickle cell disease).

Read issue
Issue 9June 9, 2026

A ~$3B M&A Monday: Incyte Buys Into Bleeding Disorders, J&J Grabs a KRAS Degrader Platform; Gilead-Merck's Once-Weekly Oral HIV Pill Clears Phase 3

A quiet ASCO-to-EHA bridge week was anchored by two June 8 US bolt-on acquisitions worth up to roughly $3.0B combined - Incyte's up-to-$2.0B purchase of Vega Therapeutics (a Phase 3 anti-Protein S antibody for von Willebrand disease) and Johnson & Johnson's $1.0B cash buy of Firefly Bio and its pan-KRAS degrader antibody conjugate platform. The same day, Gilead and Merck reported their once-weekly oral islatravir/lenacapavir regimen met its primary endpoint in two Phase 3 HIV trials. No major China-out licensing deal was announced in-window; the prior fortnight's large China-to-West pacts continue moving toward Q3 2026 closes.

Read issue

Ready to Explore a Partnership?

Whether you are seeking a licensing partner, an R&D collaborator, or strategic intelligence on the China market, we are ready to help.

Get in Touch